Are Nicotine Pouches Harmful? What the Research Actually Says
In this guide
The question gets searched constantly, and the answers available range between two unhelpful poles: unreferenced alarm that treats nicotine pouches as a public health crisis, and retailer copy that waves away genuine biological effects as irrelevant because pouches contain no tobacco.
This guide answers on the basis of published research. The BfR's own laboratory analysis of 44 products, published in October 2022. The October 2025 Cochrane Review — the most rigorous systematic review of nicotine pouches yet produced. And peer-reviewed studies on nicotine pharmacology and cardiovascular effects. We name what is known, and where the research still owes an answer.
This article is for general information only and is not medical advice. For health questions, speak with a doctor or qualified health professional.
The distinction that matters
"Are nicotine pouches harmful?" is three different questions that require different answers.
Compared to nothing: Nicotine is pharmacologically active. It is addictive, influences blood pressure and heart rate, and carries effects that become more significant over long-term use. Someone who adds a nicotine product to their life is adding something real.
Compared to cigarettes: Pouches contain no tobacco leaf, no combustion products, no tar, no carbon monoxide. The toxic substance profile is fundamentally different. This is not a marginal distinction.
What are pouches' own long-term risks? This is the question the research cannot yet answer, because nicotine pouches are too new for long-term epidemiological data to exist.
Responsible engagement with the evidence means keeping these three questions distinct rather than collapsing them into one verdict.
| Topic | Finding | Evidence quality |
|---|---|---|
| Toxic substance profile | Substantially fewer toxic substances than cigarettes. Most products contain no health-concerning substances beyond nicotine (BfR 2022). | Well established |
| Short-term serious harms | None identified in available short-term studies (Cochrane 2025). Mild effects such as mouth irritation and nausea reported. | Low certainty (few small studies) |
| Dependence potential | Nicotine is addictive. Pouches produce blood nicotine levels comparable to cigarettes (BfR 2022). | Well established |
| Cardiovascular effects | Nicotine acutely raises blood pressure and heart rate. Applies to all nicotine products including patches. No tobacco combustion products. | Nicotine effect well established; pouch-specific long-term data absent |
| Cancer / carcinogenicity | No long-term data. Trace TSNA in some BfR samples at NRT levels. Substantially fewer tobacco carcinogens than cigarettes. | Long-term data absent |
| Risk vs. cigarettes | BfR: risk-reducing potential for active smokers. Cochrane 2025: lower harmful substance biomarkers in pouch users than smokers. | Short-term established; long-term comparison absent |
What the BfR found in 44 products
Germany's Federal Institute for Risk Assessment (BfR) published its updated Opinion 023/2022 in October 2022, the most comprehensive official analysis of this product category conducted in the German-speaking region. It combined a literature review with original laboratory work on nicotine pouches drawn from the market.
Chemical composition
Most products analysed contained no health-concerning substances beyond nicotine. This distinguishes pouches fundamentally from combusted tobacco, which contains thousands of chemical compounds, including well-documented carcinogens. Trace levels of tobacco-specific nitrosamines (TSNAs) were detected in a portion of the samples. The quantities were comparable to those found in pharmaceutical nicotine replacement products like patches and gum. The BfR noted that it is technically feasible to produce pouches entirely without TSNAs, implying the traces found reflect production choices rather than inevitable product characteristics.
Nicotine absorption
Pharmacokinetic studies showed that at least half of the nicotine in a pouch is absorbed into the bloodstream. Blood nicotine levels reached were comparable to those measured after smoking conventional cigarettes. With high-dose products, blood levels were observed that significantly exceeded those from cigarette smoking. The BfR recorded nicotine content ranging from 2mg to a maximum of 47.5mg per pouch across the analysed market.
The BfR's conclusion
The BfR stated that using nicotine pouches instead of tobacco cigarettes can have a risk-reducing effect for active smokers. It simultaneously recommended regulatory standards, mandatory labelling, and quality controls. This conclusion reads as: a product with real risk potential, but a substantially more favourable toxic substance profile than cigarettes, that warrants clear regulation rather than being left unaddressed.
Context
The BfR is an independent scientific agency within the German Federal Ministry. Its opinion has been cited in administrative court proceedings regarding nicotine pouch regulation and forms part of the active regulatory debate at both federal and state level in Germany.
The 2025 Cochrane Review
In October 2025, a research group led by Jamie Hartmann-Boyce at the University of Massachusetts Amherst published the first Cochrane Review specifically on oral nicotine pouches (CD016220.pub2). Cochrane Reviews represent the highest standard in evidence-based medicine: systematic, pre-registered reviews of the entire available literature on a question.
What the review searched for
The authors searched four major scientific databases from 2000 to January 2025 plus international trial registries. They asked: Do pouches help people stop smoking or using other tobacco products? What health harms do they cause? What biomarker changes are measurable?
What they found
Despite the enormous global market penetration of nicotine pouches, after strict inclusion criteria the authors found only four qualifying randomised controlled trials covering a total of 284 participants, all smokers, conducted between 2006 and 2023. The evidence base is remarkably thin given the scale of use.
On health harms: short-term data found no serious adverse events. Mild effects including mouth irritation and nausea were reported and were generally transient.
On biomarkers: participants who switched from smoking to pouches showed lower carbon monoxide and nitrosamine levels in their bodies compared to those who continued smoking. This reflects what toxicological reasoning about the different substance profiles would predict.
On cessation: there is limited evidence that pouches can support smoking reduction, but certainty is low and the data thin. One small study found them slightly less effective than e-cigarettes for smoking cessation.
What the finding means and what it does not
"No serious short-term harms found" is not the same as "safe." It means: in the few, small, short-term studies available, no serious adverse events occurred. That is a different statement from a long-term assessment, which does not exist. The authors called urgently for larger, independent, long-term research. The review was funded by the US National Cancer Institute and FDA.
Nicotine and the cardiovascular system
In December 2025, the European Society of Cardiology (ESC) published a comprehensive policy statement in the European Heart Journal addressing nicotine's cardiovascular effects across all delivery systems, including pouches.
What is well established about nicotine
Nicotine acutely raises blood pressure and heart rate through its vasoconstrictive effect. This is documented for all nicotine-delivering products including pharmaceutical nicotine replacement therapy. A 2025 Swedish cohort study published in Harm Reduction Journal found that systolic blood pressure fell by a mean of 3.7 mmHg after twelve weeks of snus cessation, indicating measurable blood pressure influence from nicotine use.
Where the difference from cigarettes lies
The severe cardiovascular effects of smoking, including dramatically elevated risks of heart attack, stroke, and atherosclerosis, arise substantially from combustion products rather than nicotine alone. Tar, carbon monoxide, free radicals, and the thousands of other chemicals in cigarette smoke contribute to endothelial damage that pouches do not produce. The American Heart Association noted in its 2025 policy statement that no cardiovascular-specific data for nicotine pouches yet exists.
What remains open
Whether regular long-term pouch use generates independent cardiovascular risk is unknown. The question cannot be answered with the existing evidence. Anyone with existing heart disease or elevated cardiovascular risk should discuss nicotine use with a doctor.
Dependence potential
Nicotine carries a well-established dependence potential, documented across cigarettes, patches, gum, and pouches. The BfR confirmed that pouches produce blood nicotine levels comparable to cigarettes. With high-strength products, levels exceed those from smoking.
Regular pouch use can establish or sustain nicotine dependence. Withdrawal effects follow patterns common to all nicotine products: irritability, concentration difficulties, sleep disturbance, nicotine craving. What pouches differ from cigarettes on is not the dependence potential. It is the toxic substance profile.
What the research has not yet established
Long-term outcomes
Nicotine pouches are too young as a mass-market product for ten or twenty year outcome data to exist. The first generation of regular users who have been using since the early years (ZYN launched in 2014, 2016 in Europe) have not yet been observed for twelve years at scale. Long-term epidemiology simply does not exist.
Cancer risk
A 2026 review in Frontiers in Oral Health found pouches contain substantially fewer carcinogenic substances than cigarettes and tobacco snus, but that no long-term epidemiological data on cancer risk from pouch use is available. Absence of evidence is not evidence of absence, but it is also not a basis for categorical warning.
High-strength products
The BfR found products with up to 47.5mg nicotine per pouch in the market. At this level, nicotine absorption substantially exceeds that of a cigarette smoker. The risk assessment for extreme-strength products differs from that for the mainstream range of mild to strong pouches (3mg to 16mg). High-strength products warrant awareness of the significantly elevated nicotine delivery they represent.
Compared to cigarettes
The cigarette comparison is the scientifically most relevant framing, because most regular pouch users come from a tobacco background. For people who have never smoked, the relevant comparison is "compared to nothing" and the calculus is different.
Toxic substance profile: Cigarette smoke contains over 7,000 chemical compounds, including at least 70 known carcinogens. Pouches contain no tobacco leaf, no combustion products, no tar, no carbon monoxide. The substance profile is not marginally but fundamentally different.
Biomarkers: The Cochrane 2025 Review found lower CO and nitrosamine levels in people who switched from smoking to pouches, consistent with what the different substance profiles would predict.
The BfR conclusion: An independent federal scientific agency concluded that for active smokers, pouches can offer a risk-reducing alternative. This is not a marketing claim. It is a regulatory science assessment.
What is missing: Randomised controlled long-term trials comparing pouches to cigarettes with hard clinical endpoints, heart attacks, cancer rates, mortality, do not exist. Their absence is not an argument against the substance profile comparison, but it is a reason for restraint in strong claims.
Sweden's population data is regularly referenced here: Europe's lowest smoking rates and lowest smoking-related disease rates have developed alongside decades of open access to oral nicotine products, first snus and now pouches. This is an epidemiological pattern rather than proof of individual causation, but one that supports the harm reduction argument.
Frequently asked questions
Are nicotine pouches harmful?
The answer depends on the comparison. Nicotine is pharmacologically active and addictive. Pouches contain no tobacco, no combustion products, and substantially fewer harmful substances than cigarettes. The BfR (2022) found risk-reducing potential for active smokers. The Cochrane Review (2025) found no serious short-term harms in limited studies. Long-term data is absent. Not risk-free; fundamentally different from smoking.
What did the BfR find?
Germany's Federal Institute for Risk Assessment analysed nicotine pouches in its October 2022 Opinion 023/2022. Most products contained no health-concerning substances beyond nicotine. Trace TSNAs found in some samples at pharmaceutical NRT levels. Nicotine absorption produces blood levels comparable to cigarettes, exceeding them with high-dose products. BfR concluded: risk-reducing potential for smokers; recommended regulatory standards and quality controls.
What did the 2025 Cochrane Review find?
The October 2025 Cochrane Review found four qualifying studies covering 284 participants. No serious short-term health harms. Lower harmful substance biomarkers in pouch users than smokers. Limited evidence for smoking cessation support. Urgent call for larger, longer-term independent research. Funded by the US National Cancer Institute and FDA.
Are nicotine pouches addictive?
Yes. Nicotine has a well-established dependence potential. The BfR confirmed pouches produce blood nicotine levels comparable to cigarettes, with high-strength products producing levels that exceed smoking. Regular use can establish or sustain nicotine dependence with withdrawal effects equivalent to other nicotine products. The dependence potential is comparable to cigarettes; the toxic substance profile is not.
Are nicotine pouches safer than cigarettes?
The BfR stated that for active smokers, using pouches instead of cigarettes can have a risk-reducing effect. This is based on the toxic substance profile: no tobacco leaf, no combustion products, no tar, no carbon monoxide. Short-term biomarker studies show lower harmful substance levels. Long-term comparative data does not exist. Risk-reducing compared to cigarettes is not the same as risk-free.
Can nicotine pouches cause cancer?
No long-term data exists. A 2026 review in Frontiers in Oral Health found substantially fewer carcinogenic substances than cigarettes, but no long-term epidemiological data on carcinogenesis. Trace TSNAs in some BfR samples at NRT levels. Absence of evidence is not evidence of absence, but also not a basis for categorical warning.
Which strength is lowest risk?
The BfR found significant variation in nicotine content across the market, from 2mg to 47.5mg per pouch. At very high doses, blood nicotine levels substantially exceed those from smoking. Lower strength options mean lower nicotine absorption and lower vasoconstrictive load. Our strength guide explains how different brands' strength systems compare.
Last updated: April 2026. This article is for general information only and does not constitute medical advice. PouchSpot does not position nicotine pouches as a smoking cessation product or a risk-free product. For health questions, speak with a doctor.
Further reading: Pouches and Your Gums · Strength Guide · EU Regulation 2026 · PouchSpot FAQ
